王小东,刘学波

• 1:上海同济大学附属东方医院心内科

摘要(Abstract)：

<正>经皮冠状动脉介入治疗(PCI)可引起血小板活化、聚集,粥样斑块被挤压破裂,激活外源性凝血系统,凝血瀑布产生,导致血栓形成。抗凝治疗可减少PCI导致的血栓形成和栓塞。目前常用的抗凝剂有普通肝素(UFH)、低分子肝素(LMWH)、直接凝血酶抑制剂(比伐卢定、达比加群、阿加曲班)、Ⅹ因子抑制剂(利伐沙班、阿哌沙班、依度沙班)和正在研发的Ⅸ因子抑制剂等。现就PCI围术期抗凝药物的应用

关键词(KeyWords)： 经皮冠状动脉介入治疗;抗凝;低分子肝素;凝血酶抑制剂;X因子抑制剂

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王小东,刘学波

参考文献(References)：

• [1]Montalescot G,White HD,Gallo R,et al.Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.N Engl J Med,2006,355:1006-1017.
• [2]Ferguson JJ,Califf RM,Antman EM,et al.Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy:primary results of the SYNERGY randomized trial.JAMA,2004,292:45-54.
• [3]Antman EM,Morrow DA,Mc Cabe CH,et al.Enoxaparin versus unfractionated heparin with fi brinolysis for ST-elevation myocardial infarction.N Engl J Med,2006,354:1477-1488.
• [4]Anderson JL,Adams CD,Antman EM,et al.2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2013,61:e179-e347.
• [5]Bittl JA,Strony J,Brinker JA,et al.Treatment with bivalirudin(hirulog)as compared with heparin during coronary angioplasty for unstable or postinfarction angina.N Engl J Med,1995,333:764-769.
• [6]Lincoff AM,Bittl JA,Kleiman NS,et al.Comparison of bivalirudin versus heparin during percutaneous coronary intervention(the Randomized Evaluation of PCI Linking Angiomax to reduced Clinical Events[REPLACE]1 trial).Am J Cardiol,2004,93:1092-1096.
• [7]Lincoff AM,Bittl JA,Harrington RA,et al.Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention:REPLACE 2 randomized trial.JAMA,2003,289:853-863.
• [8]Parodi G,Migliorini A,Valenti R,et al.Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention(from the Antithrombotic Regimens a Nd Outcome[ARNO]trial).Am J Cardiol,2010,105:1053-1059.
• [9]Ebrahimi R,Lincoff AM,Bittl JA,et al.Bivalirudin vs heparin in percutaneous coronary intervention:a pooled analysis.J Cardiovasc Pharmacol Ther,2005,10:209-216.
• [10]De Luca G,Cassetti E,Verdoia M,et al.Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty:A meta-analyis of randomised trials.Thromb Haemost,2009,102:428-436.
• [11]Tavano D,Visconti G,D'Andrea D,et al.Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofi ban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.Am J Cardiol,2009,104:1222-1228.
• [12]Kastrati A,Neumann FJ,Schulz S,et al.Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.N Engl J Med,2011,365:1980-1989.
• [13]Mehran R,Lansky AJ,Witzenbichler B,et al.Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction(HORIZONS-AMI):1-year results of a randomised controlled trial.Lancet,2009,374:1149-1159.
• [14]Bertrand OF,Jolly SS,Rao SV,et al.Meta-Analysis Comparing Bivalirudin Versus Heparin Monotherapy on Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention.Am J Cardiol,2012,110:599-606.
• [15]Lewis BE,Matthai WH Jr,Cohen M,et al.Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.Catheter Cardiovasc Interv,2002,57:177-184.
• [16]Hirahara T,Kubo N,Ohmura N,et al.Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction[Japanese].J Cardiol,2004,44:47-52.
• [17]R.ssig L,Genth-Zotz S,Rau M,et al.Argatroban for elective percutaneous coronary intervention:the ARG E04 multi-center study.Int J Cardiol,2011,148:214-219.
• [18]Oldgren J,Budaj A,Granger CB,et al.Dabigatran vs.placebo in patients with acute coronary syndromes on dual antiplatelet therapy:a randomized,double-blind,phase II trial.Eur Heart J,2011,32:2781-2789.
• [19]Mega JL,Braunwald E,Mohanavelu S,et al.Rivaroxaban versus placebo in patients with acute coronary syndromes(ATLAS ACSTIMI 46):a randomised,double-blind,phaseⅡtrial.Lancet,2009,374:29-38.
• [20]Mega JL,Braunwald E,Wiviott SD,et al.Rivaroxaban in patients with a recent acute coronary syndrome.N Engl J Med,2012,366:9-19.
• [21]Alexander JH,Becker RC,Bhatt DL,et al.Apixaban,an oral,direct,selective factor Xa inhibitor,in combination with antiplatelet therapy after acute coronary syndrome:results of the Apixaban for Prevention of Acute Ischemic and Safety Events(APPRAISE)trial.Circulation,2009,119:2877-2885.
• [22]Alexander JH,Lopes RD,James S,et al.Apixaban with antiplatelet therapy after acute coronary syndrome.N Engl J Med,2011,365:699-708.
• [23]Mehta SR,Granger CB,Eikelboom JW,et al.Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention:results from the OASIS-5 trial.J Am Coll Cardiol,2007,50:1742-1751.
• [24]Yusuf S,Mehta SR,Chrolavicius S,et al.Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction:the OASIS-6randomized trial.JAMA,2006,295:1519-1530.